These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 17031404)

  • 21. Can morphology predict 1p/19q loss in oligodendroglial tumours?
    Scheie D; Cvancarova M; Mørk S; Skullerud K; Andresen PA; Benestad I; Helseth E; Meling T; Beiske K
    Histopathology; 2008 Nov; 53(5):578-87. PubMed ID: 18983467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
    Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D
    Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
    J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
    Smith JS; Perry A; Borell TJ; Lee HK; O'Fallon J; Hosek SM; Kimmel D; Yates A; Burger PC; Scheithauer BW; Jenkins RB
    J Clin Oncol; 2000 Feb; 18(3):636-45. PubMed ID: 10653879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
    Ramirez C; Bowman C; Maurage CA; Dubois F; Blond S; Porchet N; Escande F
    Neuro Oncol; 2010 May; 12(5):490-9. PubMed ID: 20156805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
    Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.
    Soffietti R; Nobile M; Rudà R; Borgognone M; Costanza A; Laguzzi E; Mutani R
    Cancer; 2004 Feb; 100(4):807-13. PubMed ID: 14770438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy.
    Iwadate Y; Matsutani T; Hasegawa Y; Shinozaki N; Higuchi Y; Saeki N
    J Neurooncol; 2011 May; 102(3):443-9. PubMed ID: 20721680
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype.
    Jenkinson MD; Smith TS; Brodbelt AR; Joyce KA; Warnke PC; Walker C
    J Magn Reson Imaging; 2007 Dec; 26(6):1405-12. PubMed ID: 17968881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics.
    Taal W; van der Rijt CC; Dinjens WN; Sillevis Smitt PA; Wertenbroek AA; Bromberg JE; van Heuvel I; Kros JM; van den Bent MJ
    J Neurooncol; 2015 Jan; 121(2):365-72. PubMed ID: 25344884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy of oligodendroglial tumours: current developments.
    van den Bent MJ
    Forum (Genova); 2000; 10(2):108-18. PubMed ID: 10875973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
    Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402.
    Giannini C; Burger PC; Berkey BA; Cairncross JG; Jenkins RB; Mehta M; Curran WJ; Aldape K
    Brain Pathol; 2008 Jul; 18(3):360-9. PubMed ID: 18371182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.